Compare Adaptive Biotechnologies Corp (ADPT) vs Asana Inc. (ASAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Asana Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while Asana Inc. trades at $7.25 (market cap $1.73B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Asana Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | ASAN | |
|---|---|---|
Market Cap | $3.33B | $1.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $15.35 |
52-Week Low | $10.24 | $5.46 |
Enterprise Value | $3.19B | $1.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Asana (ASAN) trades at $7.49, up 2.04% with bullish technical momentum and consistent earnings beats. The company shows strong revenue growth from $378M in 2022 to $724M in 2025, though profitability remains negative with a -20.21% net margin. Recent developments include the StackAI acquisition and FedRAMP authorization, positioning Asana in the AI workflow automation space. Analyst consensus is mixed with a $9.86 price target representing 32% upside potential from current levels.
The outlook balances growth potential against persistent losses. Revenue expansion and AI integration offer upside, but negative margins and cash flow volatility present significant execution risks. With the stock trading near analyst targets and mixed institutional sentiment, investors face a high-risk, high-reward scenario requiring careful monitoring of profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →
